Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy

Executive Summary

• Satellos Bioscience received FDA IND clearance and multiple international regulatory approvals to commence a Phase 2, placebo‑controlled study (BASECAMP) of SAT‑3247 in 51 ambulatory children with Duchenne muscular dystrophy.
• The trial will evaluate safety, tolerability, muscle force, function, quality, and regeneration over three months, with first patient enrollment expected by the end of 2025.
• Interim data are slated for release in Q2 2026 (BASECAMP) and Q1 2026 (LT‑001 adult study), positioning SAT‑3247 as a potential disease‑modifying therapy.

Key Details

• Regulatory approvals: FDA IND clearance; UK MHRA CTA authorization; Australia HREC acceptance of TGA CTN scheme; Serbia ALIMS CTA approval. EU and Canada reviews are ongoing.
• Study design: Randomized, double‑blind, placebo‑controlled, proof‑of‑concept Phase 2 trial (SAT‑3247‑CL‑201) in 51 ambulatory DMD children, duration three months.
• Primary endpoints: Safety and tolerability; effect on muscle force.
• Secondary endpoints: Muscle quality, functional performance, and regeneration metrics.
• Enrollment timeline: First participant expected by end of 2025.
• Data read‑out schedule: Interim results from BASECAMP anticipated Q2 2026; LT‑001 adult DMD study data expected Q1 2026.
• Prior clinical evidence: Phase 1a/b adult study showed SAT‑3247 was safe, well‑tolerated, and produced a ~118% mean increase in maximum grip strength (dominant hand) and ~98% increase (non‑dominant hand).
• Mechanism of action: Oral small‑molecule targeting AAK1 to restore dystrophin‑like signaling in muscle stem cells, promoting repair and regeneration independent of exon mutation status.

Notable Quotes

“We are delighted to achieve U.S. and global clearance to start our Phase 2 pediatric study… we have confidence in the potential for SAT‑3247 to make an impact for children with Duchenne,” – Frank Gleeson, Co‑founder & CEO, Satellos Bioscience.